NOVADEL FILES NDA FOR ZENSANA ORAL SPRAY

A A

NovaDel Pharma has announced the submission of a new drug application (NDA) for Zensana (Ondansetron HCl) Oral Spray to the FDA by its partner Hana Biosciences.

Zensana is the first oral spray 5-HT3 antagonist that conveniently delivers full metered doses of ondansetron faster than tablets, potentially allowing patients to gain and maintain protection from chemotherapy, radiation and post-operatively induced nausea and vomiting. Ondansetron, a selective blocking agent of the hormone serotonin, is a FDA-approved active ingredient that is commonly used in tablet form to prevent chemotherapy- and radiation-induced and post-operative nausea and vomiting.